VK2735
VANQUISH 1
Viking Therapeutics · Phase 3 · Active, not recruiting · Enrollment 4500
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Placebo Assignment | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 1) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 2) | n/r | n/r | n/r | n/r |
| Active Assignment (Dose 3) | n/r | n/r | n/r | n/r |
Not shown
- Placebo Assignment: endpoint not reported
- Active Assignment (Dose 1): endpoint not reported
- Active Assignment (Dose 2): endpoint not reported
- Active Assignment (Dose 3): endpoint not reported